Merck KGaA Rules Out Major M&A, Says MS Pill Mavenclad Will Be Major Earner

 
• By Kevin Grogan

The German group has been laying out its future plans to investors, which include reducing debt and a strong revenue stream from its Pfizer-partnered checkpoint inhibitor Bavencio.

Charts
Merck KgAA has been putting its case to the investment community • Source: Shutterstock

More from Deals

More from Business